Axelyf is a biotechnology company that offers RNA medicines through safer and more effective lipid nanoparticle delivery.
Axelyf has raised $7.4M in total funding. The most recent round was Seed. The last funding was announced in August 2025.
Axelyf's investors include Brunnur Ventures, Omega ehf, Silfurberg.
Axelyf is headquartered in Hafnarfjörður, Iceland.
Axelyf is a biotechnology company that offers RNA medicines through safer and more effective lipid nanoparticle delivery.
Axelyf is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Axelyf — Funding & Investors." VCBacked, August 7, 2025, https://www.vcbacked.co/company/axelyf. Accessed August 1, 2026.
VCBacked. (2025). Axelyf — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/axelyf
{{cite web |title=Axelyf — Funding & Investors |url=https://www.vcbacked.co/company/axelyf |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated